On June 27, 2025, the Centers for Medicare & Medicaid Services (CMS) announced a new Innovation Center payment and service delivery model aimed at reducing fraud, waste, and abuse in the Medicare ...

On July 14, 2025, the Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician Fee Schedule (PFS) proposed rule for Calendar Year (CY) 2026, which includes changes related to ...

The landscape of Medicaid eligibility is undergoing significant shifts as states increasingly pursue work requirements and other restrictive Medicaid policies, alongside broader federal discussions.

The budget reconciliation bill, known as the One Big Beautiful Bill (OBBB), a broad spending and tax bill that includes significant health care policies, was signed into law by President Trump on July ...

America’s Health Insurance Plans (AHIP)—a trade group representing the U.S. health insurance industry—announced a commitment from participating plansto improve prior authorization processes. The ...

On June 20, 2025, the Centers for Medicare & Medicaid Services (CMS) released the 2025 Marketplace Integrity and Affordability final ruleaimed at addressing improper enrollments in the ACA Health ...

A REMS letter for health care providershas been released to address the potential risk of severe hypocalcemia in patients with advanced chronic kidney disease following Jubbonti administration. More ...

As AI use has grown, payers are regularly implementing their own algorithms to deny prior authorization requests. Many of these AI algorithms are proprietary, and there is no clear guidance on if or ...

CHICAGO — Results from the international phase 3 AMPLITUDE clinical trial found that adding niraparib to abiraterone acetate (AKEEGA™) plus prednisone (AAP) can help slow cancer growth for people with ...

CHICAGO — Results from the phase 3 DESTINY-Breast09 clinical trial found that the combination of trastuzumab deruxtecan (Enhertu®) with pertuzumab (Perjeta®) can delay cancer growth for longer than ...

“This is the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer to demonstrate that post-treatment exercise is both achievable and effective in improving ...

Main Takeaway Perioperative treatment with durvalumab (Imfinzi) and chemotherapy led to longer survival without cancer recurrence, progression or treatment-related complications for patients with ...